US 12,453,773 B2
Expansion of natural killer and chimeric antigen receptor-modified cells
Dongfang Liu, Millburn, NJ (US)
Assigned to Rutgers, The State University of New Jersey, New Brunswick, NJ (US); and Houston Methodist Hospital, Houston, TX (US)
Appl. No. 17/432,380
Filed by Rutgers, The State University of New Jersey, New Brunswick, NJ (US); and Houston Methodist Hospital, Houston, TX (US)
PCT Filed Feb. 19, 2020, PCT No. PCT/US2020/018897
§ 371(c)(1), (2) Date Aug. 19, 2021,
PCT Pub. No. WO2020/172328, PCT Pub. Date Aug. 27, 2020.
Claims priority of provisional application 62/808,031, filed on Feb. 20, 2019.
Prior Publication US 2022/0152102 A1, May 19, 2022
Int. Cl. A61K 40/15 (2025.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C12N 5/0781 (2010.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)
CPC A61K 40/15 (2025.01) [A61K 38/1774 (2013.01); A61K 38/20 (2013.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61P 35/00 (2018.01); C12N 5/0635 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 15/86 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C12N 2501/2302 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2502/1107 (2013.01); C12N 2740/10043 (2013.01)] 20 Claims
 
1. A modified 721.221 cell expressing membrane-bound IL-21 (mIL-21), wherein the mIL-21 comprises an amino acid sequence comprising at least 90% or at least 95% sequence identity to SEQ ID NO: 2, and/or is encoded by a nucleic acid comprising a nucleic acid sequence comprising at least 90% or at least 95% sequence identity to SEQ ID NO: 1,
wherein the mIL-21 is present in a construct further comprising an extracellular fragment from an IgG sequence, a transmembrane fragment from a CD28 sequence, an intracellular fragment from a CD28 sequence, an intracellular fragment from a 4-1BB sequence, and an intracellular fragment from a CD3ζ sequence.